Month: September 2022

Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma – Stocks News Feed

Top-line findings were presented today at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1 inhibitor…